Delivery Order SPE2DB20D2104-SPE2DB25FMWMS
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $25,982.33 on August 21, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $12,949.95 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-set-aside award. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors, with a contract ceiling value of $44,612.34. This firm fixed-price delivery order, with an ultimate completion date of September 18, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $8,586.45 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract represents a firm fixed price, non-competitive delivery order with performance scheduled for completion by July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued as a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $27,256.30 on August 7, 2025, for the supply of Dupixent 300 mg/2 mL pen injections. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. This award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a $6,356.88 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Dupixent 200 mg/1.14 ml pen injectors. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a $20,513.52 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This competitively awarded, firm fixed price contract carries an ultimate completion date of September 15, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be...
- The Defense Logistics Agency awarded a $21,122.57 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This contract, which is a non-set-aside competitive award, represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The product will be...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMWMSDelivery Order
The Defense Logistics Agency awarded a $29,850.86 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, designated as a firm fixed price delivery order with an ultimate completion date of July 28, 2025, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's established capability to meet federal pharmaceutical procurement requirements. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies a broad range of medications and medical commodities to support military healthcare programs worldwide. The Dupixent delivery aligns with the company's extensive portfolio of specialty pharmaceutical products serving the Defense Health Agency and other federal healthcare systems across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $29.9k | 7/25/25 |